Royal Bank of Canada Has $124.46 Million Holdings in iShares Biotechnology ETF $IBB

Royal Bank of Canada increased its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 1.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 737,128 shares of the financial services provider’s stock after acquiring an additional 7,434 shares during the period. Royal Bank of Canada owned about 1.57% of iShares Biotechnology ETF worth $124,464,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its stake in iShares Biotechnology ETF by 7.9% in the first quarter. The Manufacturers Life Insurance Company now owns 62,078 shares of the financial services provider’s stock worth $10,482,000 after purchasing an additional 4,533 shares in the last quarter. Quantinno Capital Management LP increased its stake in shares of iShares Biotechnology ETF by 33.0% in the first quarter. Quantinno Capital Management LP now owns 19,892 shares of the financial services provider’s stock valued at $3,359,000 after buying an additional 4,939 shares in the last quarter. Lazard Asset Management LLC increased its stake in shares of iShares Biotechnology ETF by 28.0% in the first quarter. Lazard Asset Management LLC now owns 1,138 shares of the financial services provider’s stock valued at $192,000 after buying an additional 249 shares in the last quarter. Matrix Private Capital Group LLC bought a new position in shares of iShares Biotechnology ETF in the first quarter valued at about $68,000. Finally, Compound Planning Inc. raised its holdings in shares of iShares Biotechnology ETF by 3.9% in the first quarter. Compound Planning Inc. now owns 2,011 shares of the financial services provider’s stock valued at $340,000 after buying an additional 75 shares during the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Trading Up 0.8%

Shares of NASDAQ IBB opened at $189.96 on Friday. iShares Biotechnology ETF has a 12-month low of $130.25 and a 12-month high of $199.05. The firm’s 50-day simple moving average is $181.37 and its 200 day simple moving average is $174.56.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were paid a $0.0238 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.1%.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.